Deutschland
- Deutsch
España
- Español
Italia
- ItalianoOpioid-induced Constipation
Opioid-induced Constipation (OIC) is a common, yet frequently under-recognised and undertreated complication of opioid therapy.1
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com
Opioid-induced Constipation (OIC) is a common, yet frequently under-recognised and undertreated complication of opioid therapy.1
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com
OPIOID-INDUCED CONSTIPATION
Provided by
KKI NewCo (known as Grünenthal Meds)
MOVENTIG is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).2
Click here for prescribing information.
-
References
1. Farmer A, Drewes A, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterology Journal. 2019;7(1):7–20.
2. MOVENTIG Summary of Product Characteristics.
KKI/INT/KKI/0604 November 2023